real-estate News, Intelligence & Analysis
Jio Platforms IPO: Grey Market Premium Hits ₹225 Ahead of October 21 Launch
Goldman Sachs Offloads Eternal Shares Worth ₹169 Crore in Block Deal
Yes Bank Faces Significant Capital Reduction After Supreme Court Reverses ₹6,600 Cr AT1 Bond Write-Down
Traders Union: India's Economy Faces Dual Challenge of Sustaining Growth Amid High Inflation
IRDAI Chief: New Commission Norms Won't Disrupt Insurance Business Models
Singapore Grapples with Severe Haze; PM Wong Warns of Action Amid Disruptions
Market Overview
View allIPO Watch
View allNew Fund Offers (NFO)
View allLatest in
Biocon to Launch Cancer Drug Pebrilzo in EU/UK by 2027, US by 2028 After Settlement
Biocon has resolved all legal disputes with Genentech regarding its cancer drug Pebrilzo through a global settlement and license agreement. This crucial development paves the way for Biocon to launch Pebrilzo in the European Union and the United Kingdom by early 2027, followed by the United States in the third quarter of 2028.
BreakingHospitals, Clinics May Soon Prominently Display Service Rates
Health Secretary Punya Salila Srivastava has urged state and UT health authorities to mandate prominent display of service rates by hospitals and clinics. This move aims to help patients and their attendants understand treatment costs, make informed financial decisions, and plan their healthcare spending more effectively.
BreakingBR Shetty Sues Bank of Baroda for ₹1.25 Lakh Crore Alleging Fraud & Negligence
NMC Healthcare founder BR Shetty has filed a massive $15 billion (approximately ₹1.25 lakh crore) lawsuit against Bank of Baroda in the Bombay High Court. The suit alleges fraud and negligence, seeking damages for direct losses, consequential harm, and reputational damage.
BreakingGovernment Panel Finalises 30% Trade Margin Cap on Cancer Drugs; ₹2,500 Crore Annual Savings Expected
An expert group is finalizing a list of cancer medicines that will be subject to a new 30% trade margin cap. This government initiative aims to significantly reduce the cost of anti-cancer drugs, potentially saving Indian patients ₹2,500 crore annually and leading to retail price drops of up to 70% on some medicines.
Bayer Targets India Consumer Health Growth, Aims to Triple Revenue by 2030
Pharmaceutical giant Bayer AG plans a significant expansion of its consumer health business in India, aiming to triple its revenue by 2030. The company will focus on developing products related to digestive health, nutrition, and multivitamins, particularly those designed to counter side effects of GLP-1 drugs.
Roche Calls for Global Healthcare Overhaul to Combat Rising Chronic Disease Costs
Global pharmaceutical company Roche urges a major transformation in worldwide healthcare systems. Jorg Rupp noted current reactive models fail to tackle the growing burden of chronic diseases, leading to heavy financial demands. Roche advocates for governments to view healthcare as a crucial investment to improve health outcomes.
Bengaluru's Tricog Health Targets 10 Crore Cardiac Screenings by 2030
Bengaluru-based healthtech firm Tricog Health aims to conduct 100 million (10 crore) cardiac screenings by 2030, leveraging its AI-enabled ECG devices and specialist reviews. Since its inception in 2014, the company has already screened over 41 million patients across India and 14 other countries. This ambitious goal is set to significantly improve early detection and reduce diagnosis delays for cardiovascular diseases.
Indian Pharma Needs Digital Push to Boost Innovation, Says Kiran Mazumdar-Shaw
Biocon Chairperson Kiran Mazumdar-Shaw highlighted that Indian pharmaceutical companies are too risk-averse, hindering innovation. She urged greater adoption of digital technology to accelerate drug development and move beyond a generics-focused industry.
Drug Regulator Seeks Answers on Unapproved Medicines in National Formulary of India
India's drug regulator, DCGI, has sought an explanation from the Indian Pharmacopoeia Commission (IPC) regarding the inclusion of several unapproved drugs in the latest edition of the National Formulary of India (NFI 2026). This discrepancy raises concerns about drug safety and official guidance for medical professionals, while stakeholders also note the unavailability of its online version.
For You
View all
BreakingIndian IT Stocks Drive Dalal Street Rally Amid Global AI Slowdown
Indian IT sector stocks are currently propelling the domestic stock market higher, even as global enthusiasm for AI-driven investments appears to be waning. This indicates a notable divergence in market performance and investor sentiment between India and global tech markets.
BreakingMaruti Suzuki Wins ₹13,000 Crore Tax Dispute at ITAT
Maruti Suzuki India Ltd has received a significant financial boost after the Income Tax Appellate Tribunal (ITAT) ruled in its favour in a major tax dispute. This favourable decision is expected to have a positive impact of approximately ₹13,000 crore on the automotive giant.
BreakingSupreme Court Orders Yes Bank to Repay ₹8,415 Crore AT1 Bonds
The Supreme Court has upheld the Bombay High Court's decision, mandating Yes Bank to repay ₹8,415 crore in Additional Tier-1 (AT1) bonds. These bonds were controversially written off during the bank's restructuring in 2020. The ruling confirms that the administrator lacked the authority to write down these securities, obligating Yes Bank to repay the bondholders along with accrued interest.
BreakingIndia-US Trade Pact Nears Final Stage of Legal Drafting, Set for Soon Operation
India and the United States are in the final stages of legally drafting a crucial trade agreement, expected to become operational shortly. Union Minister Piyush Goyal confirmed the pact aims to secure preferential market access for Indian exporters and ensure tariff stability. The agreement follows extensive discussions with US trade representatives, with officials working to resolve any remaining issues before signing.
BreakingBRICS Focuses on Fertiliser Security as India Grapples with Rising Subsidy Burden
BRICS nations are discussing global fertiliser supply stability, a critical issue for India. The country faces an increasing subsidy burden to keep fertiliser prices affordable for farmers amidst volatile international markets and high import dependence.
Ather Energy Secures IRDAI Corporate Agent Licence, Enters Insurance Distribution
Electric vehicle manufacturer Ather Energy has received a Corporate Agent Licence from the Insurance Regulatory and Development Authority of India (IRDAI). This approval allows Ather Energy to now act as a corporate agent, enabling it to distribute insurance products across various categories.
Loan interest rates, processing fees and eligibility are set by the lender and subject to credit approval — verify current terms before applying. Some listings may be sponsored. Not financial advice.
Trending Now
Goldman Sachs Offloads Eternal Shares Worth ₹169 Crore in Block Deal
IRDAI Chief: New Commission Norms Won't Disrupt Insurance Business Models
India-US Trade Pact Nears Final Stage of Legal Drafting, Set for Soon Operation
Sundaram Finance Hikes Fixed Deposit Rates, Offers Up to 8% Returns
India's September Goods Exports Jump 23% to $44.4 Billion, Trade Deficit Narrows
Jio Platforms IPO: Grey Market Premium Hits ₹225 Ahead of October 21 Launch
Your AI co-pilot for markets, taxes & investing — ask anything, in your language.
